Table 2.
Clinical features and treatment of 16 patients with ipilimumab-mediated enterocolitis n (%)
| Onset of diarrhea | |
| After 1 dose of ipilimumab | 3 (19) |
| After 2 doses of ipilimumab | 7 (43) |
| After 3 doses of ipilimumab | 3 (19) |
| After 4 doses of ipilimumab | 3 (19) |
| Diarrhea details | |
| Number of bowel movements/day, median (range) | 6 (5-12) |
| Grade 2 diarrhea | 9 (56) |
| Grade 3 diarrhea | 7 (44) |
| Grade 4/5 diarrhea | 0 |
| Associated symptoms | |
| Abdominal pain | 10 (63) |
| Nausea or vomiting | 3 (19) |
| Fever | 2 (13) |
| Anorexia | 2 (13) |
| Endoscopic findings | |
| Mucosal erythema, edema, or erosions only | 6 (43) |
| Ulcers | 8 (57) |
| Treatment of diarrhea | |
| High dose corticosteroids | 16 (100) |
| Infliximab | 9 (56) |